Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2215)	2/12/2008 11:42:52 AM
From: Jibacoa	Respond to of 3722

SGP has been up 6% & still is up 5.48% after reporting smaller loss than expected.<g> bigcharts.marketwatch.com It lost $3.4B ($2.08/shr) in the quarter vs. $182M ($0.12/shr) in 2006, but without the acquisition charges,it had a profit of $0.27/shr, which was $0.03 > than the "analysts" had espected.<g> The sales for the Q were up 40% to $3.7B vs. $2.7B in 2006 with the help of Remicade sales. The 4thQ sales didn't include results from Vitorin The "analysts" have a target around $29.30 but it seems that if SGP can close above $27.80 it could get to high 30s or the $40 level.<g> bigcharts.marketwatch.com Bernard